239 related articles for article (PubMed ID: 16289487)
21. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
22. Pain hypersensitivity induced by paradoxical sleep deprivation is not due to altered binding to brain mu-opioid receptors.
Nascimento DC; Andersen ML; Hipólide DC; Nobrega JN; Tufik S
Behav Brain Res; 2007 Mar; 178(2):216-20. PubMed ID: 17239968
[TBL] [Abstract][Full Text] [Related]
23. Chronic morphine treatment induces functional delta-opioid receptors in amygdala neurons that project to periaqueductal grey.
Chieng B; Christie MJ
Neuropharmacology; 2009 Sep; 57(4):430-7. PubMed ID: 19580818
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.
Maher CE; Martin TJ; Childers SR
Life Sci; 2005 Jul; 77(10):1140-54. PubMed ID: 15890372
[TBL] [Abstract][Full Text] [Related]
25. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
26. Morphology and axonal arborization of rat spinal inner lamina II neurons hyperpolarized by mu-opioid-selective agonists.
Eckert WA; McNaughton KK; Light AR
J Comp Neurol; 2003 Apr; 458(3):240-56. PubMed ID: 12619079
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO.
Kow LM; Commons KG; Ogawa S; Pfaff DW
Brain Res; 2002 May; 935(1-2):87-102. PubMed ID: 12062477
[TBL] [Abstract][Full Text] [Related]
28. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
[TBL] [Abstract][Full Text] [Related]
29. Quantitative autoradiography of mu-opioid receptors in the CNS of high-alcohol-drinking (HAD) and low-alcohol-drinking (LAD) rats.
Learn JE; Chernet E; McBride WJ; Lumeng L; Li TK
Alcohol Clin Exp Res; 2001 Apr; 25(4):524-30. PubMed ID: 11329492
[TBL] [Abstract][Full Text] [Related]
30. Placenta ingestion by rats enhances delta- and kappa-opioid antinociception, but suppresses mu-opioid antinociception.
DiPirro JM; Kristal MB
Brain Res; 2004 Jul; 1014(1-2):22-33. PubMed ID: 15212988
[TBL] [Abstract][Full Text] [Related]
31. Genetic differences in response properties of rostral ventromedial medulla neurons to the μ-opioid receptor agonist DAMGO in mouse inbred strains.
Sugino S; Namiki A; Yamakage M
Neurosci Lett; 2012 May; 517(2):107-12. PubMed ID: 22546603
[TBL] [Abstract][Full Text] [Related]
32. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
33. Activation of mu-opioid receptor selectively potentiates NMDA-induced outward currents in rat locus coeruleus neurons.
Koyama S; Akaike N
Neurosci Res; 2008 Jan; 60(1):22-8. PubMed ID: 17976846
[TBL] [Abstract][Full Text] [Related]
34. A bi-directional mu-opioid-opioid connection between the nucleus of the accumbens shell and the central nucleus of the amygdala in the rat.
Kim EM; Quinn JG; Levine AS; O'Hare E
Brain Res; 2004 Dec; 1029(1):135-9. PubMed ID: 15533326
[TBL] [Abstract][Full Text] [Related]
35. Roles of different subtypes of opioid receptors in mediating the ventrolateral orbital cortex opioid-induced inhibition of mirror-neuropathic pain in the rat.
Zhao M; Wang JY; Jia H; Tang JS
Neuroscience; 2007 Feb; 144(4):1486-94. PubMed ID: 17184926
[TBL] [Abstract][Full Text] [Related]
36. Sustained inhibition of neurotransmitter release from nontransient receptor potential vanilloid type 1-expressing primary afferents by mu-opioid receptor activation-enkephalin in the spinal cord.
Zhou HY; Chen SR; Chen H; Pan HL
J Pharmacol Exp Ther; 2008 Nov; 327(2):375-82. PubMed ID: 18669865
[TBL] [Abstract][Full Text] [Related]
37. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologically selective block of mu opioid antinociception by peptide nucleic acid antisense in absence of detectable ex vivo knockdown.
Pradhan AA; Clarke PB
Eur J Pharmacol; 2005 Jan; 506(3):229-36. PubMed ID: 15627432
[TBL] [Abstract][Full Text] [Related]
39. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
[TBL] [Abstract][Full Text] [Related]
40. Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury.
Hurley RW; Hammond DL
J Neurosci; 2001 Apr; 21(7):2536-45. PubMed ID: 11264327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
